Key Findings
On July 23, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for the new hypercholesterolemia drug, Evlarco (obicetrapib / ezetimibe). This oral medication is recommended for the treatment of primary hypercholesterolemia or mixed dyslipidemia as an adjunct to diet. Evlarco, presented as film-coated tablets, combines obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, and ezetimibe, a cholesterol absorption inhibitor, aiming for efficient reduction of low-density lipoprotein cholesterol (LDL-C).
Technical / Clinical Details
Evlarco provides a comprehensive approach to cholesterol management by combining two drugs with distinct mechanisms of action:
- Obicetrapib: As a CETP inhibitor, it blocks the activity of cholesteryl ester transfer protein (CETP). CETP is an enzyme involved in the transfer of cholesteryl esters from HDL cholesterol to LDL cholesterol. Its inhibition is expected to lower LDL-C levels and raise high-density lipoprotein cholesterol (HDL-C) levels.
- Ezetimibe: This drug selectively inhibits cholesterol absorption in the small intestine. It reduces the amount of dietary and biliary cholesterol absorbed into the body, thereby lowering blood cholesterol levels.
By combining these two agents, each contributing to LDL-C reduction through different pathways, Evlarco is expected to achieve potent lipid-lowering effects that may be difficult to attain with monotherapy. The formulation as film-coated tablets also considers patient convenience.
Background & Context
Hypercholesterolemia and mixed dyslipidemia are major risk factors for cardiovascular disease and have a high global prevalence. While statins are widely used as existing treatments, some patients show insufficient response or have tolerability issues. Although some CETP inhibitors in the past failed to demonstrate cardiovascular event reduction, obicetrapib is evaluated for its favorable balance of LDL-C reduction and HDL-C elevation. The combination with ezetimibe will offer a new and important treatment option for patients intolerant to statins or those unable to reach target LDL-C levels with statin monotherapy. The development of such novel combination drugs reflects the pharmaceutical industry’s continuous efforts to address diverse patient needs.
Strategic Significance & Outlook
A positive CHMP opinion typically leads to final marketing authorization by the European Commission. If Evlarco is approved in the European market, it will provide an effective and convenient new treatment option for patients with hypercholesterolemia and mixed dyslipidemia. This is expected to contribute to further reducing cardiovascular disease risk. Future focus will be on long-term safety data for Evlarco and its impact on cardiovascular events. Furthermore, amidst ongoing competition in the development of drugs with similar mechanisms, how Evlarco penetrates the market will be an important focal point.
Source: https://www.ema.europa.eu/en/medicines/human/EPAR/evlarco
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments